Public health economics of vaccines in the Netherlands: Methodological issues and applications

Journal of Public Health

Volumn 16, Issue 4, 2008, Pages 267-273

  Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Human papilloma vaccine; Immunisation policy; Meningococcal C vaccine; Pneumococcal vaccine; Public health economics

Indexed keywords

MENINGOCOCCUS VACCINE; NEISVAC; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; HERD IMMUNITY; MENINGOCOCCOSIS; MONEY; NEISSERIA MENINGITIDIS; NETHERLANDS; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; REIMBURSEMENT; REPEATED DRUG DOSE; REVIEW; STREPTOCOCCUS INFECTION; VERRUCA VULGARIS;

EID: 48149100248     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-008-0200-2     Document Type: Review

References (26)

1. JM Bos H Rumke R Welte MJ Postma 2003 Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands Clin Ther 25 2614 2630
2. JM Bos P Beutels L Annemans MJ Postma 2004 Valuing prevention through economic evaluation; some considerations regarding the choice of discount model for health effects with focus on infectious diseases Pharmacoeconomics 22 1171 1179
3. WBF Brouwer LW Niessen MJ Postma 2005 Need for differential discounting of costs and health effects in cost effectiveness analysis BMJ 331 446 448
4. MF Drummond C Chevat M Lothgren 2007 Do we fully understand the economic value of vaccines? Vaccine 25 5945 5957
5. H Gravelle W Brouwer L Niessen 2007 Discounting in economic evalutations: stepping forward to optimal decision rules Health Economics 16 307 317
6. Foundation for Health Care Insurance (College voor Zorgverzekeringen; CvZ) (1999) Guidelines for pharmacoeconomic research. Amstelveen
7. Foundation for Health Care Insurance (College voor Zorgverzekeringen; CvZ) (2004) Updated guidelines for pharmacoeconomic research. Diemen
8. Health Council (GezondheidsRaad; GR) (2002) Universal Vaccination against Meningococci and Pneumococci (in Dutch). The Hague
9. Health Council (GezondheidsRaad; GR) (2004) Vaccination against Pertussis (in Dutch). The Hague: GR
10. Health Council (GezondheidsRaad; GR) (2005) Vaccination of Infants against Pneumococcal Infections (in Dutch). The Hague
11. Health Council (GezondheidsRaad; GR) (2007) The Future of the National Immunization Program; towards a program for all ages (in Dutch). The Hague
12. Health Council (GezondheidsRaad; GR) (2008) Vaccination against Cervical Cancer (in Dutch). The Hague
13. BMS Heeg E Buskens M Knapp 2005 Modelling the treated course of schizophrenia: Development of a discrete event simulation model Pharmacoeconomics 23 S1 17 33
14. BMS Heeg RJG Peters M Botteman A van Hout 2007 Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Pharmacoeconomics 25 769 783
15. GAA Hubben JM Bos DM Glynn 2007 Enhanced decision support for policy makers using a web interface to health-economic models-Illustrated with a cost-effectiveness analysis of nation-wide vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands Vaccine 25 3669 3678
16. CA Lexau R Lynfield R Danila 2005 Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine JAMA 294 2043 2051
17. MJ Postma 2003 Pharmacoeconomic research Pharmacy, World & Science 25 245 246
18. MJ Postma P Jansema HWKFH Scheijbeler MLL van Genugten 2005 Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults Vaccine 23 5365 5371
19. Postma MJ, Nijman HW, Daemen CAHH et al (2007a) Cost-effectiveness of Human Papilloma Virus (HPV) 16/18 Vaccines against Cervical Cancer in the Netherlands. Vaccine Vaccine Congress 9-11 Dec 2007; Abstract Book
20. MJ Postma A Novak HWKFH Scheijbeler M Gyldmark MLL van Genugten JC Wilschut 2007 Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza; illustration for the Netherlands Pharmacoeconomics 25 6 497 509
21. F Rutten 2004 Health technology assessment and policy from the economic perspective Int J Technol Assess Health Care 20 67 70
22. EA Stolk JJV Busschbach M Caffa 2000 Cost utility analysis of sildenafil compared with papaverine-phentolamine injections BMJ 320 1165 1168
23. Thiry N, Lambert M-L, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, De Laet Ch (2007) HPV Vaccinatie ter Preventie van Baarmoederhalskanker in België. Brussels: Federaal Kenniscentrum voor de Gezondheidszorg (KCE)
24. R Welte G van den Dobbelsteen JM Bos 2004 Economic evaluation of menigococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision making Vaccine 23 470 479
25. R Welte CL Trotter WJ Edmunds 2005 The role of economic evaluation in vaccine decision making Pharmacoeconomics 23 855 474
26. CG Whitney MM Farley J Hadler 2003 Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide vaccine N Engl J Med 348 1737 1746